AFP、CA125、CA199联合检测在原发性肝癌诊断中的应用价值

Application Value of Combined Detection of AFP, CA125 and CA199 in Diagnosis of Primary Liver Cancer

目的探讨肿瘤标记物甲胎蛋白(AFP)及糖类抗原CA125、CA199在原发性肝癌(PHC)诊断中的应用价值。方法将80例PHC患者作为A组,同时期76例良性肝病患者作为B组,80例健康人员作为C组,采用电化学发光法检测三组人员的AFP、CA125、CA199水平。结果 A组AFP、CA125、CA199水平明显高于B组及C组,B组AFP、CA125、CA199水平明显高于C组,差异有统计学意义(P<0.05);AFP、CA125、CA199联合检测敏感性高于单一检测,差异有统计学意义(P<0.05)。结论肿瘤标志物联合检测可有效提高PHC及良性肝病的检出率,尤其对AFP检测阴性、低浓度的PHC更具有临床价值。

Objective To investigate application value of tumor markers of alpha fetoprotein（AFP） and carbohydrate antigen CA125, CA199 in diagnosis of primary liver cancer（PHC）. Methods Treat 80 cases PHC patients as group A, 76 cases benign liver disease patients as group B at same period, 80 cases healthy people as group C. Detect AFP, CA125 and CA199 level of three groups by electrochemiluminescence. Results AFP, CA125, CA199 level of was significantly higher than group B and C, AFP, CA125 and CA199 level of B group was significantly higher than group C, difference showed statistical significance（P〈0.05）; sensitivity of AFP, CA125, CA199 combined detection is higher than single detection, difference showed statistical significance（P〈0.05）. Conclusion Combined detection of tumor markers can improve detection rate of PHC and benign liver diseases effectively, is of clinical value for PHC with negative AFP and low concentration especially.